Therapeutic Solutions Intl Inc Stock Price, News & Analysis

On February 8, 2021, Therapeutic Solutions International (TSOI) announced a new patent application revealing that StemVacs can induce 'memory' in natural killer (NK) cells, a breakthrough not previously associated with innate immunity. Experiments showed that mice treated with StemVacs exhibited regression of B16 melanoma tumors, and NK cells transferred to untreated mice conferred resistance to melanoma. This suggests StemVacs could convert 'cold' tumors into 'hot' ones, enhancing efficacy in immunotherapy. The company is exploring partnerships, viewing this data as a significant opportunity for business growth.

Therapeutic Solutions International (OTC Markets: TSOI) has signed a Master Sales Agreement with Community Shield LLC to distribute its science-based nutraceutical products, including QuadraMune™ and NanoCannabidiol. This partnership aims to enhance product awareness and sales in the multibillion-dollar nutraceutical market. TSOI emphasizes a 'science first' approach, with products backed by laboratory and clinical data. The agreement is seen as a significant milestone in TSOI's strategy of leveraging external partnerships for growth.

On Feb. 1, 2021, Therapeutic Solutions International, Inc. (OTC Markets: TSOI) presented new findings showing that exosomes from its cellular immunotherapy product, StemVacs, can effectively promote regression in an animal model of glioma. These exosomes stimulate natural killer cells, leading to cancer suppression, countering earlier beliefs about cancer exosomes. The company is also exploring regulatory pathways with the FDA to potentially submit an Investigational New Drug application for exosome use. The immunotherapy sector is seeing increasing interest, as exemplified by high valuations of similar firms.

Therapeutics Solutions International (OTC: TSOI) announced successful preclinical studies showing NanoStilbene™, a nanotechnology-based formulation of pterostilbene, significantly reduces neurological damage in a model of multiple sclerosis. Compared to Copaxone™, NanoStilbene™ demonstrated superior effects in alleviating brain inflammation and symptoms. Executives emphasize its neuroprotective potential and the importance of thorough scientific development. The company is also conducting a clinical trial for QuadraMune™, a nutraceutical aimed at reducing COVID-19 infections.

Therapeutic Solutions International (TSOI) appointed Serena Robella as the new Director of Sales, effective October 12, 2020. Her role will focus on expanding the company’s market presence within the $70 billion nutraceutical sector through enhanced physician engagement and social media strategies. Robella's expertise in brand building and sales is expected to strengthen TSOI's operations. The company is also advancing its clinical trial for QuadraMune™ targeting COVID-19 prevention. TSOI holds an exclusive license for the FDA-cleared JadiCell™ stem cell therapy.

Therapeutics Solutions International, Inc. (OTC Markets: TSOI) announced the appointment of J Christopher Mizer to its Campbell Neurosciences Division Advisory Board on October 5, 2020. The Campbell Neurosciences Division focuses on suicide prevention, developing the Campbell Score™ blood-based risk prediction test, integrative nutraceuticals, and the Campbell Protocol™. Mizer, a seasoned entrepreneur with over 25 years of experience, aims to contribute to addressing the core causes of mental illness, working with notable advisors including Dr. Santosh Kesari.

Therapeutics Solutions International (OTC Markets: TSOI) announced positive preclinical data showcasing its JadiCell therapy's superior neuro-regenerative capabilities compared to other cell therapies. Collaborators observed enhanced stem cell proliferation in the dentate gyrus regions of animal models and demonstrated neuron protection from inflammation-related cell death. The FDA has cleared JadiCell for clinical trials for other uses, and efforts are underway to file an Investigational New Drug application to initiate trials targeting Chronic Traumatic Encephalopathy, a serious condition affecting veterans.

Therapeutics Solutions International (OTC: TSOI) launched Neuroleukin™, a personalized biological product aimed at preventing suicide by utilizing specific cells from a patient's blood to block harmful brain chemicals. The product has demonstrated proof of concept both in vitro and in vivo, with plans for pilot clinical trials. Neuroleukin™ combines patient-derived products and specific ingredients to reduce brain inflammation and enhance neurotransmitter production. Due to its origins from the patient's own blood, the company anticipates a streamlined path to market without full FDA trials.

Therapeutics Solution International (TSOI) announced the filing of a landmark patent for stem cell-based immunotherapy aimed at treating schizophrenia, which affects about 1% of the population. This patent includes over 1000 claims, covering various stem cell types and therapies to mitigate symptoms and enhance treatment responses. The innovative Campbell Platform provides personalized treatment assessments based on inflammatory markers and exosome evaluations. The JadiCell technology, licensed to TSOI, shows promise in neuro-related applications, particularly in suicide prevention and brain injuries.